Levels and values of lipoprotein-associated phospholipase A2, galectin-3, RhoA/ROCK, and endothelial progenitor cells in critical limb ischemia: Pharmaco-therapeutic role of cilostazol and clopidogrel combination therapy

Journal of Translational Medicine

Volumn 12, Issue 1, 2014, Pages

  Sheu, Jiunn Jye ^a   Lin, Pao Yuan ^a   Sung, Pei Hsun ^a   Chen, Yi Ching ^a   Leu, Steve ^b   Chen, Yung Lung ^a   Tsai, Tzu Hsien ^a   Chai, Han Tan ^a   Chua, Sarah ^a   Chang, Hsueh Wen ^c   Chung, Sheng Ying ^a   Chen, Chih Hung ^b   Ko, Sheung Fat ^a   Yip, Hon Kan ^a,b  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^c NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

Author keywords

Cilostazol therapy; Clopidogrel; Critical limb ischemia; Endothelial progenitor cells; Inflammation

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; CILOSTAZOL; CLOPIDOGREL; GALECTIN 3; MESSENGER RNA; RHO KINASE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; ANTITHROMBOCYTIC AGENT; PRIMER DNA; TETRAZOLE DERIVATIVE; TICLOPIDINE;

AGED; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CRITICAL LIMB ISCHEMIA; DRUG MECHANISM; ENDOTHELIAL PROGENITOR CELL; ENZYME ACTIVITY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HUMAN; LP PLA2 GENE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WOUND HEALING; ANALOGS AND DERIVATIVES; CYTOLOGY; DRUG COMBINATION; ISCHEMIA; LIMB; METABOLISM; NUCLEOTIDE SEQUENCE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VASCULARIZATION;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; AGED; BASE SEQUENCE; DNA PRIMERS; DRUG THERAPY, COMBINATION; ENDOTHELIAL PROGENITOR CELLS; EXTREMITIES; FEMALE; GALECTIN 3; HUMANS; ISCHEMIA; MALE; PLATELET AGGREGATION INHIBITORS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RHO-ASSOCIATED KINASES; TETRAZOLES; TICLOPIDINE;

EID: 84899914944     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-12-101     Document Type: Article

References (47)

1. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993, 362:801-809. 10.1038/362801a0, 8479518.
2. van der Wal AC, Becker AE, van der Loos CM, Das PK. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 1994, 89:36-44. 10.1161/01.CIR.89.1.36, 8281670.
3. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999, 340:115-126. 10.1056/NEJM199901143400207, 9887164.
4. Yip HK, Wu CJ, Chang HW, Yang CH, Yeh KH, Chua S, Fu M. Levels and values of serum high-sensitivity C-reactive protein within 6 hours after the onset of acute myocardial infarction. Chest 2004, 126:1417-1422. 10.1378/chest.126.5.1417, 15539707.
5. Yip HK, Wu CJ, Yang CH, Chang HW, Fang CY, Hung WC, Hang CL. Serial changes in circulating concentrations of soluble CD40 ligand and C-reactive protein in patients with unstable angina undergoing coronary stenting. Circ J 2005, 69:890-895. 10.1253/circj.69.890, 16041155.
6. Hiatt WR. Medical treatment of peripheral arterial disease and claudication. N Engl J Med 2001, 344:1608-1621. 10.1056/NEJM200105243442108, 11372014.
7. Hirsch AT, Criqui MH, Treat-Jacobson D, Regensteiner JG, Creager MA, Olin JW, Krook SH, Hunninghake DB, Comerota AJ, Walsh ME, McDermott MM, Hiatt WR. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001, 286:1317-1324. 10.1001/jama.286.11.1317, 11560536.
8. Ouriel K. Peripheral arterial disease. Lancet 2001, 358:1257-1264. 10.1016/S0140-6736(01)06351-6, 11675083.
9. Dormandy J, Heeck L, Vig S. The fate of patients with critical leg ischemia. Semin Vasc Surg 1999, 12:142-147.
10. Yip HK, Chen SS, Liu JS, Chang HW, Kao YF, Lan MY, Chang YY, Lai SL, Chen WH, Chen MC. Serial changes in platelet activation in patients after ischemic stroke: role of pharmacodynamic modulation. Stroke 2004, 35:1683-1687. 10.1161/01.STR.0000131658.80951.c3, 15155956.
11. Yip HK, Chang LT, Sun CK, Chen MC, Yang CH, Hung WC, Hsieh YK, Fang CY, Hang CL, Wu CJ, Chang HW. Platelet activity is a biomarker of cardiac necrosis and predictive of untoward clinical outcomes in patients with acute myocardial infarction undergoing primary coronary stenting. Circ J 2006, 70:31-36. 10.1253/circj.70.31, 16377921.
12. Yip HK, Lu CH, Yang CH, Chang HW, Hung WC, Cheng CI, Chen SM, Wu CJ. Levels and value of platelet activity in patients with severe internal carotid artery stenosis. Neurology 2006, 66:804-808. 10.1212/01.wnl.0000208220.04165.05, 16567695.
13. Libby P, Geng YJ, Sukhova GK, Simon DI, Lee RT. Molecular determinants of atherosclerotic plaque vulnerability. Ann N Y Acad Sci 1997, 811:134-142. discussion 142-135, 10.1111/j.1749-6632.1997.tb51996.x, 9186592.
14. Stafforini DM, Elstad MR, McIntyre TM, Zimmerman GA, Prescott SM. Human macrophages secret platelet-activating factor acetylhydrolase. J Biol Chem 1990, 265:9682-9687.
15. Asano K, Okamoto S, Fukunaga K, Shiomi T, Mori T, Iwata M, Ikeda Y, Yamaguchi K. Cellular source(s) of platelet-activating-factor acetylhydrolase activity in plasma. Biochem Biophys Res Commun 1999, 261:511-514. 10.1006/bbrc.1999.1066, 10425216.
16. Tsai TH, Chen YL, Lin HS, Liu CF, Chang HW, Lu CH, Chang WN, Chen SF, Wu CJ, Leu S, Ko SF, Yip HK. Link between lipoprotein-associated phospholipase A2 gene expression of peripheral-blood mononuclear cells and prognostic outcome after acute ischemic stroke. J Atheroscler Thromb 2012, 19:523-531. 10.5551/jat.10751, 22447189.
17. Barondes SH, Cooper DN, Gitt MA, Leffler H. Galectins. Structure and function of a large family of animal lectins. J Biol Chem 1994, 269:20807-20810.
18. Cooper DN. Galectinomics: finding themes in complexity. Biochim Biophys Acta 2002, 1572:209-231. 10.1016/S0304-4165(02)00310-0, 12223271.
19. Henderson NC, Mackinnon AC, Farnworth SL, Kipari T, Haslett C, Iredale JP, Liu FT, Hughes J, Sethi T. Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am J Pathol 2008, 172:288-298. 10.2353/ajpath.2008.070726, 2312353, 18202187.
20. Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 2000, 275:2247-2250. 10.1074/jbc.275.4.2247, 10644669.
21. de Boer RA, Yu L, van Veldhuisen DJ. Galectin-3 in cardiac remodeling and heart failure. Curr Heart Fail Rep 2010, 7:1-8. 10.1007/s11897-010-0004-x, 2831188, 20425490.
22. Tsai TH, Sung PH, Chang LT, Sun CK, Yeh KH, Chung SY, Chua S, Chen YL, Wu CJ, Chang HW, Ko SF, Yip HK. Value and level of galectin-3 in acute myocardial infarction patients undergoing primary percutaneous coronary intervention. J Atheroscler Thromb 2012, 19:1073-1082. 10.5551/jat.12856, 23037954.
23. Noma K, Oyama N, Liao JK. Physiological role of ROCKs in the cardiovascular system. Am J Physiol Cell Physiol 2006, 290:C661-C668. 2692274, 16469861.
24. Nakagawa O, Fujisawa K, Ishizaki T, Saito Y, Nakao K, Narumiya S. ROCK-I and ROCK-II, two isoforms of Rho-associated coiled-coil forming protein serine/threonine kinase in mice. FEBS Lett 1996, 392:189-193. 10.1016/0014-5793(96)00811-3, 8772201.
25. Wei L, Roberts W, Wang L, Yamada M, Zhang S, Zhao Z, Rivkees SA, Schwartz RJ, Imanaka-Yoshida K. Rho kinases play an obligatory role in vertebrate embryonic organogenesis. Development 2001, 128:2953-2962.
26. Ridley AJ, Hall A. The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. Cell 1992, 70:389-399. 10.1016/0092-8674(92)90163-7, 1643657.
27. Wojciak-Stothard B, Williams L, Ridley AJ. Monocyte adhesion and spreading on human endothelial cells is dependent on Rho-regulated receptor clustering. J Cell Biol 1999, 145:1293-1307. 10.1083/jcb.145.6.1293, 2133155, 10366600.
28. Laufs U, Liao JK. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem 1998, 273:24266-24271. 10.1074/jbc.273.37.24266, 9727051.
29. Ming XF, Viswambharan H, Barandier C, Ruffieux J, Kaibuchi K, Rusconi S, Yang Z. Rho GTPase/Rho kinase negatively regulates endothelial nitric oxide synthase phosphorylation through the inhibition of protein kinase B/Akt in human endothelial cells. Mol Cell Biol 2002, 22:8467-8477. 10.1128/MCB.22.24.8467-8477.2002, 139860, 12446767.
30. Yip HK, Wu CJ, Hang CL, Chang HW, Hung WC, Yeh KH, Yang CH. Serial changes in platelet activation in patients with unstable angina following coronary stenting: evaluation of the effects of clopidogrel loading dose in inhibiting platelet activation. Circ J 2005, 69:1208-1211. 10.1253/circj.69.1208, 16195618.
31. Ferreiro JL, Bhatt DL, Ueno M, Bauer D, Angiolillo DJ. Impact of Smoking on Long-Term Outcomes in Patients with Atherosclerotic Vascular Disease Treated with Aspirin or Clopidogrel: Insights from the Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE) Trial. J Am Coll Cardiol 2014, 63:769-777. 10.1016/j.jacc.2013.10.043, 24239662.
32. Bhatt DL, Topol EJ,. Clopidogrel for High Atherothrombotic R, Ischemic Stabilization M, Avoidance Executive C Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Am Heart J 2004, 148:263-268. 10.1016/j.ahj.2004.03.028, 15308995, Clopidogrel for High Atherothrombotic R, Ischemic Stabilization M, Avoidance Executive C.
33. Pan X, Arauz E, Krzanowski JJ, Fitzpatrick DF, Polson JB. Synergistic interactions between selective pharmacological inhibitors of phosphodiesterase isozyme families PDE III and PDE IV to attenuate proliferation of rat vascular smooth muscle cells. Biochem Pharmacol 1994, 48:827-835.
34. Kubota Y, Kichikawa K, Uchida H, Maeda M, Nishimine K, Makutani S, Sakaguchi S, Yoshioka T, Ohishi H, Kimura Y, Yoshikawa T. Pharmacologic treatment of intimal hyperplasia after metallic stent placement in the peripheral arteries. An experimental study. Invest Radiol 1995, 30:532-537. 10.1097/00004424-199509000-00004, 8537210.
35. Douglas JS, Holmes DR, Kereiakes DJ, Grines CL, Block E, Ghazzal ZM, Morris DC, Liberman H, Parker K, Jurkovitz C, Murrah N, Foster J, Hyde P, Mancini GB, Weintraub WS,. Cliostazol for restonsis trial (CREST) investigators Coronary stent restenosis in patients treated with cilostazol. Circulation 2005, 112:2826-2832. 10.1161/CIRCULATIONAHA.104.530097, 16246948, Cliostazol for restonsis trial (CREST) investigators.
36. Margolis DJ, Allen-Taylor L, Hoffstad O, Berlin JA. Diabetic neuropathic foot ulcers: the association of wound size, wound duration, and wound grade on healing. Diabetes Care 2002, 25:1835-1839. 10.2337/diacare.25.10.1835, 12351487.
37. Yip HK, Chang LT, Chang WN, Lu CH, Liou CW, Lan MY, Liu JS, Youssef AA, Chang HW. Level and value of circulating endothelial progenitor cells in patients after acute ischemic stroke. Stroke 2008, 39:69-74. 10.1161/STROKEAHA.107.489401, 18063830.
38. Mukai Y, Shimokawa H, Matoba T, Kandabashi T, Satoh S, Hiroki J, Kaibuchi K, Takeshita A. Involvement of Rho-kinase in hypertensive vascular disease: a novel therapeutic target in hypertension. FASEB J 2001, 15:1062-1064.
39. Liu PY, Liu YW, Lin LJ, Chen JH, Liao JK. Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation. Circulation 2009, 119:131-138. 10.1161/CIRCULATIONAHA.108.813311, 2745913, 19075102.
40. Dong M, Liao JK, Fang F, Lee AP, Yan BP, Liu M, Yu CM. Increased Rho kinase activity in congestive heart failure. Eur J Heart Fail 2012, 14:965-973. 10.1093/eurjhf/hfs068, 3707433, 22588320.
41. Boden WE, O'Rourke RA, Teo KK, Maron DJ, Hartigan PM, Sedlis SP, Dada M, Labedi M, Spertus JA, Kostuk WJ, Berman DS, Shaw LJ, Chaitman BR, Mancini GB, Weintraub WS,. COURAGE trial investigators Impact of optimal medical therapy with or without percutaneous coronary intervention on long-term cardiovascular end points in patients with stable coronary artery disease (from the COURAGE Trial). Am J Cardiol 2009, 104:1-4. 10.1016/j.amjcard.2009.02.059, 19576311, COURAGE trial investigators.
42. Sheu JJ, Lin KC, Tsai CY, Tsai TH, Leu S, Yen CH, Chen YL, Chang HW, Sun CK, Chua S, Yang JL, Yip HK. Combination of cilostazol and clopidogrel attenuates rat critical limb ischemia. J Transl Med 2012, 10:164. 10.1186/1479-5876-10-164, 3479044, 22897925.
43. Chan YC, Cheng SW. Drug-eluting stents and balloons in peripheral arterial disease: evidence so far. Int J Clin Pract 2011, 65:664-668. 10.1111/j.1742-1241.2011.02639.x, 21564438.
44. Buechel R, Stirnimann A, Zimmer R, Keo H, Groechenig E. Drug-eluting stents and drug-coated balloons in peripheral artery disease. Vasa 2012, 41:248-261. 10.1024/0301-1526/a000200, 22825858.
45. Mongiardo A, Curcio A, Spaccarotella C, Parise S, Indolfi C. Molecular mechanisms of restenosis after percutaneous peripheral angioplasty and approach to endovascular therapy. Curr Drug Targets Cardiovasc Haematol Disord 2004, 4:275-287. 10.2174/1568006043336258, 15379621.
46. Goetz JG, Joshi B, Lajoie P, Strugnell SS, Scudamore T, Kojic LD, Nabi IR. Concerted regulation of focal adhesion dynamics by galectin-3 and tyrosine-phosphorylated caveolin-1. J Cell Biol 2008, 180:1261-1275. 2290850, 18347068.
47. Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J Clin Invest 2005, 115:3378-3384. 10.1172/JCI27196, 1297269, 16322783.